Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Éric Gervais, executive vice-president of Duchesnay Inc, a privately-held, specialty Canadian pharma company focusing on women’s health, charts the company’s successful growth over the past 25 years, the innovative portfolio…
Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and…
Ronnie Miller, President & CEO of Roche Canada, shares the lessons learnt over his 17 years heading the affiliate, the interesting dynamics and developments within the Canadian healthcare space, Roche’s…
Dr. Roman Szumski, vice-president of life sciences at the National Research Council (NRC), Canada’s industrial innovation and research organization, highlights the strategic and operational changes that have occurred over the…
Clarissa Desjardins is the founder and CEO since 2011 of Canadian biotech success story, Clementia Pharmaceuticals. She explains the different milestones of her company and her priorities moving forward. She…
With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is facing somewhat of an existential crisis. However, within this difficult market environment, enterprising generics companies are…
Chirfi Guindo, president and managing director of Merck Canada, highlights the stunning transformation that has led to a revitalized new Merck affiliate, the innovation opportunities Canada’s fragmented and diverse health…
Newly appointed minister of health of Canada, The Honourable Ginette Petitpas Taylor, shares the core tenets of her mandate, the Federal government’s priorities for investment into the Canadian healthcare ecosystem,…
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Paul-Émile Cloutier, president & CEO of HealthCareCAN, the national voice of healthcare organizations and hospitals across Canada, highlights his ambition to make HealthCareCAN the go-to resource on healthcare system topics,…
Mark Lachovsky, founder and president of Accel Pharma, a Canadian generics company with a unique business model, discusses the inspiring story of how he started and grew the company through…
Brian Hilberdink, President of Novo Nordisk Canada, highlights the key role that Canada plays as a pilot market for exporting best practices globally, the focus that Novo Nordisk is placing…
See our Cookie Privacy Policy Here
